Celltrion Seo Jung-jin

South Korea’s pharmaceutical giant Celltrion Inc. has won final approval for its COVID-19 treatment Regkirona from the European Commission, a ...

Cash-strapped South Korean budget airlines are rushing to raise money in the local stock market on growing hopes for a travel recovery as government...

South Korea’s pharmaceutical conglomerate Celltrion Group has made its very first step in reforming corporate governance structure by merging ...

South Korean drugmaker Celltrion Inc. has added Brazil to the list of countries that have granted emergency use approval for its COVID-19 treatment ...

South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, followi...

South Korean drugmaker Celltrion Inc. has received the Indonesian government’s permission for restricted use of its COVID-19 treatment Regkiro...

Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by ...

South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...

Actress Youn Yuh-jung has made history by becoming the first Korean actor to win an Oscar at the Academy Awards, held in Los Angeles Sunday night.&n...

South Korea-based Celltrion Inc. has alluded to the possibility of developing a COVID-19 vaccine on the grounds that securing a vaccine is essential...

Celltrion Inc. and HLB Inc., two leading South Korean biopharmaceutical shares, shot up on Monday as the main bourse’s key index climbed back ...

South Korea's Celltrion Inc. has completed second-phase clinical trials of its COVID-19 treatment and is seeking conditional approval of its distr...

South Korea's biopharmaceutical firm Celltrion Inc. has completed the $278 million acquisition of Takeda Pharmaceutical Company Ltd's primary care a...

South Korea’s biopharmaceutical firm Celltrion Inc. can unveil an antibody treatment by around the end of the year that is able to kill the COVI...

South Korean biosimilar maker Celltrion Inc's operating profit topped market expectations by more than 20% in the third quarter, hitting a record high...

Seo Jung-jin, founder and chairman of South Korea’s biosimilar maker Celltrion Group, said on Oct. 6 that he is in talks with a number of global...

South Korea’s Celltrion Inc. and its affiliates are expected to post robust operating profits this year on the back of strong sales of Remsima a...

South Korea’s Celltrion Inc. on Sept. 10 rebutted J.P. Morgan’s massive downgrade of its target price for the biopharmaceutical company. T...

Kim Yong-jin, the former second vice finance minister of President Moon Jae-in’s government between mid-2017 and 2018, has been chosen as the Na...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...

One Equity Partners (OEP), a New York based private equity firm, unloaded its remaining shares in Celltrion Healthcare valued at approximately 31...